Amerikanische Gesellschaft für Hirudotherapie

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction

Retrospective study published in Microsurgery (2014)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienPannucci CJ et al. · Microsurgery, 2014

Abstract

BACKGROUND: Free tissue transfer is an accepted method for breast reconstruction. Surgically uncorrectable venous congestion is a rare but real occurrence after these procedures. Here, we report our experience with the management of surgically uncorrectable venous congestion after free flap breast reconstruction using medicinal leech therapy. METHODS: We queried our prospectively maintained institutional database for all patients with venous congestion after free flap breast reconstruction since 2005. Chart review was performed for all patients having post-operative venous congestion. We compared patients with surgically correctable venous congestion and surgically uncorrectable venous congestion requiring medicinal leech therapy. RESULTS: Twenty-three patients had post-operative venous congestion, and four of these patients were surgically uncorrectable requiring medicinal leech therapy. Patients who required leech therapy had lower hemoglobin nadirs, received more blood transfusions, and received a higher number of total units of red blood cells than patients who did not require leech therapy. Among four patients who required leech therapy, one flap was partially salvaged and three flaps were completely lost. Leech therapy was associated with higher total flap loss rates (75.0% vs. 42.1%) and longer length of stay (8.0 ± 3.6 days vs. 6.5 ± 2.1 days) when compared to non-leeched flaps. These differences were not statistically significant (P = 0.32 and P = 0.43, respectively). CONCLUSIONS: In patients with surgically uncorrectable venous congestion after free flap breast reconstruction, total flap loss is common despite leech therapy. When venous congestion cannot be corrected, total flap removal may be a better option than attempted salvage with leech therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsFemaleFree Tissue FlapsHumansHyperemiaLeechingMammaplastyMiddle AgedPostoperative ComplicationsRetrospective StudiesSalvage Therapy

Zusammenfassung

In 4 patients with surgically uncorrectable venous congestion after free flap breast reconstruction, leech therapy yielded 75% total flap loss with higher transfusion requirements versus surgically corrected cases.

Warum dies für die Hirudotherapie relevant ist

This retrospective study reviewed medicinal leech therapy for surgically uncorrectable venous congestion after free flap breast reconstruction, identifying 4 leech-treated cases among 23 with postoperative venous congestion; leech-treated patients had lower hemoglobin nadirs and more transfusions, and among the 4, one flap was partially salvaged and three were completely lost (75% total flap loss), with differences versus non-leeched flaps not statistically significant. For ASH, this is relevant as clinical outcome data on hirudotherapy in a specific, challenging reconstructive setting where surgical correction has failed. Honest caveat: this is a small retrospective series (only 4 leech-treated patients) with no statistical power; the authors themselves conclude that total flap loss is common despite leech therapy and that flap removal may be a better option in such cases.

Zitation

Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction.

Pannucci CJ et al. · Microsurgery, 2014

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.